Doxil (Pegylated Liposomal Doxorubicin) [doxorubicin liposomal], Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

Trial Profile

Doxil (Pegylated Liposomal Doxorubicin) [doxorubicin liposomal], Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Status changed from withdrawn prior to enrolment to completed.
    • 16 Feb 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Primary endpoint identified as response rate as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top